Ann: Shareholder Briefing, page-100

Thanks heaps Wardy, for your summary.

What kind of results in July are going to be considered good enough to entice interest for partnering?

I think the simple answer is in slide #6 in the presentation, which suggests that 27% of patients showing at least an extra 50% reduction in proteinuria "would be seen as a clinically relevant result, and highly competitive with other development stage drugs with real potential to improve patient quality of life"

So putting thing simply, when the results are out in July is it going to be as simple as ensuring the responder rate is at 27% or higher???

What are everyone's thoughts on this %? Seems a bit low? Anyone know what sort of success rates (and side effects) other treatments offer?

If no adverse side effects are apparent with DMX200 and patients actually get to remain on their existing blood pressure treatment, then a 27% chance of complete remission using a daily oral drug would be highly valuable to a ckd sufferer.